Oct 9, 2026Latest
12.0/15
Fundamental
4/5
The company posts an outstanding ROE (53.4%) and steady revenue growth (19.3% YoY). The key risks remain its high leverage (D/E of 197.5%) and weak current liquidity (current ratio of 0.73).
Sentiment
4/5
Excellent Q1 2026 results that beat the market consensus markedly improved sentiment around the company. The analysts’ average target price is 206.28 PLN, implying meaningful upside.
Strategy
4/5
The defensive, cycle-resilient healthcare sector is an excellent fit for long-term strategies. A regular dividend policy (4.40 PLN per share) and steady acquisitions support stable growth.
Target price (AI estimate)
206.28 zł
Risk flags
Snapshot
Financial position & key ratios
Diagnostyka S.A. (DIA) is the undisputed leader of Poland’s medical laboratory market. The current share price of 171.90 PLN sits above the 50-day moving average (163.95 PLN) but below the 200-day average (180.80 PLN). On profitability the company impresses with an ROE of 53.41% and steady double-digit revenue growth (19.3% YoY). The weaker side of the balance sheet is liquidity – a current ratio of 0.73 – and high net debt relative to equity (197.49%), both stemming from the nature of its rapid expansion and the leasing of medical infrastructure. At a P/E of 22.21 the market valuation already prices in considerable growth expectations from investors.
Search
Market sentiment & recommendations
The consensus among analysts covering the company is highly optimistic and points unambiguously to a buy rating. The average target price set by experts is 206.28 PLN, which at the current price implies roughly 20% upside for the shares. Recent brokerage analyses and valuations place fair value in the 188 PLN to 217 PLN range. Positive investor sentiment was further reinforced after the May quarterly report, which dispelled concerns about a slowdown in the group’s organic growth.
Press
Latest events & dividend
The most important catalyst for the shares recently was the first-quarter 2026 results. The company reported net profit of 82.55 million PLN (up nearly 13% YoY), clearly beating market expectations of 72.5 million PLN. Sales revenue rose 13.4% YoY to 670.9 million PLN. In parallel, the Annual General Meeting of 25 May 2026 approved a 2025 dividend of 4.40 PLN per share, giving a dividend yield of about 2.54%. The record date fell on 2 June, with the payment date set for 16 June 2026. Strategically, management signalled scaling back capital-intensive acquisitions in imaging diagnostics in favour of developing high-margin B2C services that do not require NFZ (public payer) contracts. In the first quarter alone, however, the company completed as many as 8 smaller acquisitions of laboratory operators for a combined 31.9 million PLN.
Verdict
Summary & outlook
Diagnostyka S.A. proves it can effectively monetize its dominant market position, generating stable cash flows. The combination of the defensive nature of the medical sector, solid earnings growth and a regularly paid dividend (4.40 PLN/share) makes the company an attractive proposition for investors building a long-term income portfolio. The main risk factor remains its high leverage, which in an environment of elevated interest rates could raise the cost of financing further acquisitions. The key to sustaining the rally will be the successful integration of the acquired laboratories and success in winning private (B2C) customers, which will help keep margins high.
